New therapies in hemophilia: extend the half-life, mimic, or rebalance?

The treatment landscape for hemophilia has evolved rapidly over the past decade, with the approval of several therapies with novel mechanisms of action. Extended half-life factor concentrates and nonfactor therapies, including factor VIII mimetics an…

Preview only. Read the full abstract at the source